Cipla signs license agreement with Salix

Grants exclusive rights for 'Rifaximin Complexes' patent to Salix

Cipla announced that it has signed an agreement with Salix Pharmaceuticals, Inc., a US-based speciality pharmaceutical company.

Under the agreement, Cipla has granted Salix exclusive rights under certain patent applications in the 'Rifaximin Complexes' patent family controlled by Cipla.

The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the 'Rifaximin Complexes' patent rights. Salix also will pay a royalty on net sales of products covered by the 'Rifaximin Complexes' patents licensed to Salix.

Powered by Capital Market - Live News